Intellia Therapeutics (NTLA) to Offer Up to $150M in Common Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/1/2026
- Equities turn higher as Treasury yields drop from highs
- Fed’s Jefferson sees no urgency for another rate increase
- Oil jumps 4% on reports China halts fuel exports, US troops head to Middle East
- Amazon and these four U.S. stocks are latest additions to Goldman’s flagship list
- Anthropic targets mid-November for public debut - report
- Zimbabwe helicopter crash kills six, government spokesperson says
- Apple's iOS 27 is blocking Trade Desk ads on Safari, analyst says
- DataMeds AI's Corexa Pharmacy tops $1M in monthly revenue
- S&P 500 dips, Nasdaq higher after data shows moderate inflation rise
- Micron Technology (MU) Tops Q4 EPS by $2.26, Offers Guidance
Intellia Therapeutics (NTLA)Prices 4.795M Share Common Offering at $36.50/Sh
December 2, 2020 6:04 AM ESTIntellia Therapeutics, Inc. (NASDAQ: NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, announced today the pricing of an underwritten public offering of 4,794,521 shares of its common stock at... More
